{"id":39213,"date":"2025-08-13T13:20:36","date_gmt":"2025-08-13T05:20:36","guid":{"rendered":"https:\/\/flcube.com\/?p=39213"},"modified":"2025-08-13T13:20:36","modified_gmt":"2025-08-13T05:20:36","slug":"bayer-collaborates-with-kumquat-biosciences-to-develop-kras-g12d-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39213","title":{"rendered":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor"},"content":{"rendered":"\n

German pharmaceutical giant Bayer AG (ETR: BAYN<\/a>) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat’s KRAS G12D inhibitor. This strategic partnership combines Kumquat’s innovative drug development capabilities with Bayer’s extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.<\/p>\n\n\n\n

Collaboration Details<\/strong>
Under the terms of the agreement, Kumquat Biosciences will initiate and complete the Phase Ia study for its KRAS G12D inhibitor. Bayer will assume responsibility for all subsequent development and commercialization activities. This collaboration model leverages the strengths of both companies to expedite the drug’s progression from early-stage trials to potential market approval.<\/p>\n\n\n\n

Financial Terms<\/strong>
Kumquat Biosciences stands to receive up to $1.3 billion under the agreement. This includes an upfront payment, clinical and commercial milestone payments, and tiered royalties on net sales. Additionally, Kumquat retains an exclusive option to negotiate for profit-and-loss sharing in the U.S., further aligning the interests of both parties in the drug’s success.<\/p>\n\n\n\n

Regulatory Progress<\/strong>
Kumquat Biosciences received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of its KRAS G12D inhibitor in July 2025. This regulatory milestone paves the way for the Phase Ia study to proceed, marking a significant step forward in the clinical development of this potential oncology treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August…<\/p>\n","protected":false},"author":1,"featured_media":39216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[269,16,967,4279],"class_list":["post-39213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bayer","tag-cancer","tag-etr-bayn","tag-kumquat-biosciences"],"yoast_head":"\nBayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39213\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39213\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T05:20:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor\",\"datePublished\":\"2025-08-13T05:20:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213\"},\"wordCount\":247,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1306.webp\",\"keywords\":[\"Bayer\",\"Cancer\",\"ETR: BAYN\",\"Kumquat Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39213#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39213\",\"name\":\"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1306.webp\",\"datePublished\":\"2025-08-13T05:20:36+00:00\",\"description\":\"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39213\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39213#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39213","og_locale":"en_US","og_type":"article","og_title":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor","og_description":"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.","og_url":"https:\/\/flcube.com\/?p=39213","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-13T05:20:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39213#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39213"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor","datePublished":"2025-08-13T05:20:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39213"},"wordCount":247,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39213#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","keywords":["Bayer","Cancer","ETR: BAYN","Kumquat Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39213#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39213","url":"https:\/\/flcube.com\/?p=39213","name":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39213#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39213#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","datePublished":"2025-08-13T05:20:36+00:00","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat's KRAS G12D inhibitor. This strategic partnership combines Kumquat's innovative drug development capabilities with Bayer's extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39213#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39213"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39213#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","width":1080,"height":608,"caption":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39213#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39213"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39213\/revisions"}],"predecessor-version":[{"id":39217,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39213\/revisions\/39217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39216"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}